B

Bavarian Nordic A/S
CSE:BAVA

Watchlist Manager
Bavarian Nordic A/S
CSE:BAVA
Watchlist
Price: 187.5 DKK -0.9%
Market Cap: 14.9B DKK
Section:
 

Relative Value

The Relative Value of one BAVA stock under the Base Case scenario is hidden DKK. Compared to the current market price of 187.5 DKK, Bavarian Nordic A/S is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

BAVA Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Valuation Multiples

2.1
P/S
P/S
Price to Sales
2.1
vs History
79
vs Industry
76
Median 3Y
2.4
Median 5Y
3.5
Industry
7.8
Forward
2.3
More Details
6
P/E
P/E
Price to Earnings
6
vs History
58
vs Industry
9
Median 3Y
12.3
Median 5Y
9.2
Industry
24.1
Forward
11.4
More Details
4.7
P/OCF
P/OCF
Price to OCF
4.7
vs History
63
vs Industry
14
Median 3Y
10.4
Median 5Y
7.6
Industry
21.8
More Details
12.3
P/FCFE
P/FCFE
Price to FCFE
12.3
vs History
22
vs Industry
3
Median 3Y
-7.7
Median 5Y
-12.3
Industry
23.8
More Details
1.1
P/B
P/B
Price to Book Value
1.1
vs History
92
vs Industry
58
Median 3Y
1.4
Median 5Y
1.6
Industry
3.3
More Details
1.7
EV/S
EV/S
Enterprise Value to Sales
1.7
vs History
87
vs Industry
68
Median 3Y
2.2
Median 5Y
3.2
Industry
8
Forward
1.9
More Details
3.2
EV/GP
EV/GP
Enterprise Value to Gross Profit
3.2
vs History
80
vs Industry
62
Median 3Y
4
Median 5Y
5.3
Industry
10.3
More Details
3.7
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
3.7
vs History
74
vs Industry
13
Median 3Y
6.6
Median 5Y
6.6
Industry
6.3
Forward
5.7
More Details
4.8
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
4.8
vs History
58
vs Industry
10
Median 3Y
9.1
Median 5Y
7.1
Industry
6.7
Forward
8.1
More Details
3.8
EV/OCF
EV/OCF
Enterprise Value to OCF
3.8
vs History
63
vs Industry
15
Median 3Y
9.2
Median 5Y
6.6
Industry
7.9
More Details
9.3
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
9.3
vs History
30
vs Industry
3
Median 3Y
-9.8
Median 5Y
-11.7
Industry
6.3
More Details
1.1
EV/IC
EV/IC
Enterprise Value to IC
1.1
vs History
71
vs Industry
57
Median 3Y
1.2
Median 5Y
1.4
Industry
5.5
More Details

Multiples Across Competitors

BAVA Competitors Multiples
Bavarian Nordic A/S Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
DK
Bavarian Nordic A/S
CSE:BAVA
14.7B DKK 2.1 6 3.7 4.8
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 861 489.7 -160 938.6 -195 430.8 -193 200.7
US
Abbvie Inc
NYSE:ABBV
400.9B USD 6.7 170.7 16.5 23.4
US
Amgen Inc
NASDAQ:AMGN
176.1B USD 4.9 25.1 18.1 18.1
US
Gilead Sciences Inc
NASDAQ:GILD
154.4B USD 5.3 19 12.8 12.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
115.9B USD 9.9 31.5 23.1 24.2
US
Epizyme Inc
F:EPE
94.1B EUR 2 080.5 -530.9 -578.1 -562.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
80.9B USD 5.7 17.7 16.8 19.1
AU
CSL Ltd
ASX:CSL
85.6B AUD 3.6 18.9 12.7 15.9
NL
argenx SE
XBRU:ARGX
44.8B EUR 14.6 34.3 59.1 60.8
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
52.7B USD 16.4 1 210.8 159.1 192.9
P/E Multiple
Earnings Growth PEG
DK
B
Bavarian Nordic A/S
CSE:BAVA
Average P/E: 170.4
6
-4%
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -160 938.6 N/A N/A
US
Abbvie Inc
NYSE:ABBV
170.7
89%
1.9
US
Amgen Inc
NASDAQ:AMGN
25.1
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
19
190%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
31.5
N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -530.9 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.7
9%
2
AU
CSL Ltd
ASX:CSL
18.9
11%
1.7
NL
argenx SE
XBRU:ARGX
34.3
40%
0.9
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
1 210.8
N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
DK
B
Bavarian Nordic A/S
CSE:BAVA
Average EV/EBITDA: 35.8
3.7
4%
0.9
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -195 430.8 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.5
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
18.1
11%
1.6
US
Gilead Sciences Inc
NASDAQ:GILD
12.8
7%
1.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23.1
16%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -578.1 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.8
11%
1.5
AU
CSL Ltd
ASX:CSL
12.7
8%
1.6
NL
argenx SE
XBRU:ARGX
59.1
807%
0.1
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
159.1
N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
DK
B
Bavarian Nordic A/S
CSE:BAVA
Average EV/EBIT: 41.3
4.8
8%
0.6
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -193 200.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.4
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
18.1
20%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
12.8
12%
1.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24.2
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -562.7 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
19.1
13%
1.5
AU
CSL Ltd
ASX:CSL
15.9
11%
1.4
NL
argenx SE
XBRU:ARGX
60.8
N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
192.9
N/A N/A

See Also

Summary
BAVA intrinsic value, competitors valuation, and company profile.
DCF Valuation
BAVA stock valuation using Discount Cash Flow valuation method.
Relative Valuation
BAVA stock valuation using valuation multiples.
Wall Street Estimates
BAVA price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
BAVA stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 304,500+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.